| Fcγ receptors: genetic variation, function, and disease CE Hargreaves, MJJ Rose‐Zerilli, LR Machado, C Iriyama, EJ Hollox, ... Immunological reviews 268 (1), 6-24, 2015 | 102 | 2015 |
| Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: an association study and meta-analysis MJ Simmonds, FK Kavvoura, OJ Brand, PR Newby, LE Jackson, ... The Journal of Clinical Endocrinology & Metabolism 99 (1), E127-E131, 2014 | 92 | 2014 |
| The role of genomics in common variable immunodeficiency disorders AK Kienzler, CE Hargreaves, SY Patel Clinical & Experimental Immunology 188 (3), 326-332, 2017 | 82 | 2017 |
| Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves’ disease CE Hargreaves, M Grasso, CS Hampe, A Stenkova, S Atkinson, ... The Journal of Immunology 190 (11), 5373-5381, 2013 | 81 | 2013 |
| Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412 K Hussain, CE Hargreaves, A Roghanian, RJ Oldham, HTC Chan, ... Blood, The Journal of the American Society of Hematology 125 (1), 102-110, 2015 | 74 | 2015 |
| Impact of human FcγR gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format K Hussain, CE Hargreaves, TF Rowley, JM Sopp, KV Latham, P Bhatta, ... Frontiers in immunology 10, 390, 2019 | 22 | 2019 |
| Evaluation of high-throughput genomic assays for the Fc gamma receptor locus CE Hargreaves, C Iriyama, MJJ Rose-Zerilli, SQ Nagelkerke, K Hussain, ... PLoS One 10 (11), e0142379, 2015 | 19 | 2015 |
| Association of FcGRIIa with Graves’ disease: a potential role for dysregulated autoantibody clearance in disease onset/progression K Yesmin, C Hargreaves, PR Newby, OJ Brand, JM Heward, JA Franklyn, ... Clinical endocrinology 73 (1), 119-125, 2010 | 13 | 2010 |
| Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma JC Strefford, M Nowicka, CE Hargreaves, C Burton, A Davies, ... Blood advances 5 (15), 2935-2944, 2021 | 12 | 2021 |
| A novel, heterozygous three base-pair deletion in CARD11 results in B cell expansion with NF-κB and T cell anergy disease AM Shields, BM Bauman, CE Hargreaves, AJ Pollard, AL Snow, SY Patel Journal of Clinical Immunology 40, 406-411, 2020 | 12 | 2020 |
| HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy K Hussain, R Liu, RCG Smith, KTJ Müller, M Ghorbani, S Macari, ... Journal of Experimental & Clinical Cancer Research 41 (1), 131, 2022 | 11 | 2022 |
| Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment M Nowicka, LK Hilton, M Ashton-Key, CE Hargreaves, C Lee, R Foxall, ... Blood advances 5 (15), 2945-2957, 2021 | 8 | 2021 |
| Decreased ATM function causes delayed DNA repair and apoptosis in common variable immunodeficiency disorders CE Hargreaves, S Salatino, SC Sasson, JEG Charlesworth, E Bateman, ... Journal of Clinical Immunology 41 (6), 1315-1330, 2021 | 7 | 2021 |
| Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy C Jamois, E Gibiansky, L Gibiansky, V Buchheit, D Sahin, G Cartron, ... British Journal of Clinical Pharmacology 85 (7), 1495-1506, 2019 | 7 | 2019 |
| Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants CE Hargreaves, F Dhalla, AM Patel, ACG De Oteyza, E Bateman, J Miller, ... Clinical Immunology 234, 108910, 2022 | 6 | 2022 |
| Prognostic impact of germ-line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) single nucleotide polymorphisms in lymphoma patients treated with obinutuzumab or rituximab in … JC Strefford, M Nowicka, C Hargreaves, C Iriyama, KV Latham, ... Blood 132, 4109, 2018 | 3 | 2018 |
| An analysis of the rise, use, evolution and value of Anglo-American commando and special forces formations, 1939-1945 AL Hargreaves King's College London, 2008 | 2 | 2008 |
| Correction: evaluation of high-throughput genomic assays for the Fc gamma receptor locus CE Hargreaves, C Iriyama, MJJ Rose-Zerilli, SQ Nagelkerke, K Hussain, ... Plos one 11 (3), e0145040, 2016 | 1 | 2016 |
| FCGR2A-131H/H is under-represented amongst patients with primary immunodeficiencies EWD Flewitt, JEG Charlesworth, SY Patel, CE Hargreaves medRxiv, 2023.10. 12.23296440, 2023 | | 2023 |
| Abstract PO-26: Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal … LK Hilton, M Nowicka, M Ashton-Key, CE Hargreaves, C Lee, R Foxall, ... Blood Cancer Discovery 1 (3_Supplement), PO-26-PO-26, 2020 | | 2020 |
